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Abstract - This study explores responses to ketamine in 
patients with treatment-resistant depression (TRD) using 
a wearable forehead electroencephalography (EEG) 
device. We recruited and randomly assigned 55 
outpatients with TRD into three approximately equal-
sized groups (A: 0.5 mg/kg ketamine; B: 0.2 mg/kg 
ketamine; and C: normal saline) under double-blind 
conditions. The ketamine responses were measured by 
EEG signals and Hamilton Depression Rating Scale 
(HDRS) scores. At baseline, the responders showed 
significantly weaker EEG theta power than the non-
responders (p < 0.05). Compared to baseline, the 
responders exhibited higher EEG alpha power but lower 
EEG alpha asymmetry and theta cordance post-
treatment (p < 0.05). Furthermore, our baseline EEG 
predictor classified the responders and non-responders 
with 81.3 ± 9.5% accuracy, 82.1 ± 8.6% sensitivity and 
91.9 ± 7.4% specificity. In conclusion, the rapid 
antidepressant effects of mixed doses of ketamine are 
associated with prefrontal EEG power, asymmetry and 
cordance at baseline and early post-treatment changes. 
Prefrontal EEG patterns at baseline may serve as 
indicators of ketamine effects. Our randomized, double-
blind, placebo-controlled study provides information 
regarding the clinical impacts on the potential targets 
underlying baseline identification and early changes 
from the effects of ketamine in patients with TRD.  
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I. INTRODUCTION1 
EPRESSION is a common affective disorder with a high 
prevalence worldwide (4.5% - 37.4%), and the incidence 
of major depressive disorder ranges from 4.6% to 9.3%. 
Current traditional antidepressants, including selective 
serotonin reuptake inhibitors, serotonin norepinephrine 
reuptake inhibitors and norepinephrine and dopamine 
reuptake inhibitors, have been used to treat depression 
individually or in combination. Approximately 30-40% of 
patients with major depression do not respond to traditional 
antidepressants, and a patient with major depression who 
does not respond to at least two clinical trials of traditional 
antidepressants during an adequate period is considered to 
have treatment-resistant depression (TRD) [1]. Patients with 
TRD have traditionally been defined as patients with no 
response or an inadequate response; however, recent clinical 
studies have shown significant improvements in depressive 
symptoms after a low-dose ketamine treatment. Ketamine, 
which is an NMDA receptor antagonist, differs from 
traditional antidepressants, which all act on monoamine 
systems. In contrast, ketamine acts on the glutamate system 
in the brain. The discovery and replication of the rapid and 
robust antidepressant effects of ketamine on TRD symptoms 
may represent an important achievement, addressing some 
limitations of current antidepressant treatments, such as a 
longer latency to become effective. Additionally, low-dose 
ketamine has been noted to have robust and rapid 
antidepressant effects, specifically in patients with TRD [2-
4].  
Depressive symptoms are associated with brain cortical 
abnormalities, and the prefrontal cortex (PFC) is critically 
involved in the neuro-circuitry of depression [5]. Depressive 
disorders are correlated with a reduction in dorsolateral PFC 
gray matter volumes and unique directional changes in the 
prefrontal cortex [6, 7]. Furthermore, as shown in our 
previous studies involving patients with TRD, glucose 
metabolism in the PFC is correlated with ketamine responses 
[4], and these patients continued to present abnormal glucose 
metabolism in the PFC after aggressive treatments [8, 9]. 
Therefore, the PFC is a potential indicator reflecting the 
neurophysiological activity of patients with TRD. 
Electroencephalography (EEG), which features non-
invasive electrodes placed along the scalp, is an 
electrophysiological monitoring method used to record 
spontaneous electrical activity in the brain [10]. EEG has 
been widely used to study antidepressant treatment responses 
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in many clinics due to its broad availability and cost-
effectiveness [11, 12]. The development of dry sensors has 
resulted in wearable EEG headbands with dry electrodes that 
are more convenient for measuring EEG signals than 
conventional EEG headsets with wet electrodes. Dry 
electrodes avoid the use of conductive gel and skin 
preparation while transmitting brainwaves that are 
encountered with wet electrodes [13, 14].  
The relationship between the antidepressant response and 
prefrontal EEG dynamics, particularly measurements 
derived from theta and alpha activity, has attracted 
significant interest [12, 15-17]. Alpha activity has an 
inhibitory effect on cortical network activity; thus, increased 
alpha power has been observed in depressed patients who 
respond to antidepressant treatment [18]. Some studies have 
also reported antidepressant treatment responses in 
association with hemispheric asymmetry, which is a relative 
measure of the difference in EEG alpha power between the 
right and left prefrontal regions that reflects relatively 
lateralized cortical activity [19]. While left versus right 
hemispheric activation has been associated with treatment 
responses, a body of literature has raised the possibility of 
hemispheric asymmetry in the alpha band [11, 18, 20, 21]. 
Similarly, conflicting studies have investigated theta activity 
and reported that increased absolute theta power [22] or 
decreased relative theta power [17] is associated with the 
treatment response. To determine the emergent effectiveness 
of antidepressant therapy, theta cordance [23] has been 
derived from both absolute and relative theta power. Prior 
studies have shown decreased frontal theta cordance after 
antidepressant treatment [24, 25]. Additionally, “pre-
exposure EEG” may capture the trait aspects of 
psychological dysfunction [26], suggesting that a baseline 
(pre-treatment) EEG has the potential to predict the effects 
of antidepressants in an individual. These EEG patterns, 
which are correlated with the response to antidepressants, 
potentially represent the neurophysiological activities in 
patients with TRD. 
According to a literature review, the derived EEG features 
demonstrate various trends from the baseline to post-
treatment that may be associated with different types of 
antidepressants. However, whether the responses of TRD 
patients to ketamine involve the dynamics of prefrontal EEG 
and whether discriminative EEG can be used as a potential 
feature to predict the ketamine response remain unclear. The 
novelty of this study involves the dynamics of prefrontal 
EEG to investigate the responses of patients with TRD to 
ketamine treatment instead of traditional antidepressants. 
Because antidepressants exert their effects on PFC activation 
and EEG dynamics, the a priori hypothesis is that the rapid 
antidepressant effects of different doses of ketamine are 
correlated with baseline and early changes in EEG patterns 
in the prefrontal area similar to the time-dependent effects of 
some traditional antidepressants. Consistent with previous 
studies [27-29], our study proposes to investigate prefrontal 
EEG patterns (e.g., power, asymmetry and cordance) at the 
baseline level (-10 to 0 min) and early post-treatment 
changes (240-250 min after drug infusion) to determine the 
signatures of the ketamine response under randomized, 
double-blind, placebo-controlled conditions. Additionally, 
the discriminative EEG patterns at baseline may help TRD 
patients understand ketamine’s effects and could potentially 
be used in daily life via a wearable forehead EEG device. To 
the best of our knowledge, no studies have investigated brain 
dynamics to identify ketamine responses in TRD patients 
using a wearable forehead EEG; thus, this novel study could 
contribute to biomedical engineering and clinical 
applications. In this study, we used a wearable EEG system 
and advanced data analysis approaches to investigate TRD 
patients using ketamine as an antidepressant. 
This paper is organized as follows. First, Section II 
introduces the participant recruitment, experimental 
procedures, data processing and statistical analysis used in 
this study. Section III presents the experimental results, 
including the demographic characteristics and clinical and 
treatment responses, comparisons between groups, and 
predictor performance. Section V discusses the experimental 
results, future directions and limitations. Section VI provides 
the conclusion.  
 
II. MATERIALS AND METHODS 
A. Subjects 
Outpatients with depression were recruited at the 
Psychiatric Department of Taipei Veterans General Hospital 
(VGH). The patients’ diagnoses were based on the criteria 
from the Diagnostic and Statistical Manual of Mental 
Disorders IV Text Revision (DSM-IV-TR) for the diagnosis 
of major depressive disorder. In addition, the included 
patients did not have major medical or neurological illnesses. 
The enrolled patients were required to have a poor treatment 
history with at least two different antidepressants (with 
sufficient dosages and treatment periods) and at least one 
invalid effort with adequate antidepressant treatment during 
their current depressive episode to ensure that each subject 
was resistant to antidepressant medications. Patients were 
excluded if they received a structured diagnostic Mini 
International Neuropsychiatric Interview (MINI) [30] 
conducted by a board-certified psychiatrist (TPS) to confirm 
the diagnosis.  
The Hamilton Depression Rating Scale-17 (HDRS-17) 
[31] is the most widely used clinician-administered 
depression assessment scale for evaluating antidepressants’ 
effects. This questionnaire, which was designed for adults, is 
used to rate the severity of patients’ depression by probing 
their mood, feelings of guilt, suicidal ideation, insomnia, 
agitation or retardation, anxiety, weight loss and somatic 
symptoms. The original version contains 17 items pertaining 
to symptoms of depression experienced over the previous 
week. A score of 0–7 is considered normal, while a score of 
20 or higher (indicating at least moderate severity) is usually 
required for entry into a clinical trial. 
Patients with a history of bipolar disorder, psychotic 
depression or substance/alcohol abuse or a score of less than 
18 on the HDRS-17 at screening and less than 13 at the start 
of infusion were excluded from the study. Patients with 
comorbid Axis I diagnoses of anxiety disorders were 
permitted due to the ubiquity of these disorders among 
patients with major depressive disorder (MDD). This study 
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was approved by the Institutional Review Board of the 
Taipei VGH (2012-04-037B), and informed consent was 
obtained from all subjects before entry into the study. This 
clinical trial was registered with the UMIN Clinical Trials 
Registry (UMIN000016985) on June 30, 2016. Additionally, 
all experimental procedures were performed in accordance 
with the relevant guidelines and regulations. 
 
B. Experimental Procedures 
Each patient received a clinical assessment, including a 
psychiatric profile, medical history and assessment of 
medication use. The patients with TRD were divided into the 
following three subgroups at an approximate 1:1:1 ratio: 
group A-0.5 mg/kg ketamine, group B-0.2 mg/kg ketamine, 
and group C-normal saline (NS). This subgroup allocation 
was conducted under randomized and double-blind 
conditions by an independent nurse who was not involved in 
our study. The experiments were performed in a quiet, dimly 
lit room at psychiatric inpatient unit D020 of Taipei VGH. 
During the first two minutes of the experiment, the patients 
were instructed to take several deep breaths while they 
adapted to the environment. A specific wearable EEG 
recording system (Fig. 1A) called the “Mindo-4S Jellyfish” 
(Brain Rhythm Inc., Zhubei District, Hsinchu, Taiwan) that 
used a 16-bit quantization level at a sampling rate of 512 Hz 
was used in this study; the system included four dry 
electrodes (Fp1, Fp2, AF7 and AF8) in the prefrontal region, 
a reference electrode (A2) [13, 14] and a built-in real-time 
EEG signal enhancement to remove artifacts [32]. These dry 
electrodes are more convenient for measuring EEG signals 
than conventional wet electrodes and are preferred because 
they avoid the use of conductive gel and skin preparation 
while achieving a signal quality comparable to that of wet 
electrodes [13, 14].  
Specifically, a real-time artifact removal algorithm based 
on canonical correlation analysis (CCA), feature extraction, 
and a Gaussian mixture model (GMM) were used to improve 
the quality of the EEG signals. The CCA was used to 
decompose the EEG signals into components, followed by 
feature extraction to extract the representative features and 
GMM to cluster these features into groups to recognize and 
remove artifacts. The feasibility of the proposed algorithm 
was demonstrated by effectively removing artifacts caused 
by blinks, head/body movement, and chewing from the EEG 
recordings. Furthermore, the dry EEG sensors enabled the 
continuous monitoring of the high-temporal resolution brain 
dynamics without requiring the application of conductive 
gels on the scalp. The long-term impedance measurements 
suggest that compared to other gel electrode types, the dry 
EEG sensors have the potential to provide stable EEG signals. 
Notably, our developed mobile and wireless EEG system 
features a dry micro-electromechanical system with 
electroencephalography sensors, low-power signal 
acquisition, amplification and digitization, wireless 
telemetry, online artifact enhancement, and signal pre-
processing. The test of our EEG system showed promising 
and consistent EEG signal qualities for all subjects [13, 14]. 
Then, as shown in Fig. 1B, the patients were instructed to 
close their eyes as the EEG signals were recorded for 
approximately 10 min (baseline, 1st session). Subsequently, 
an infusion of 0.5 mg/kg ketamine, 0.2 mg/kg ketamine or 
NS was administered over the course of 40 min. Notably, the 
patients always experienced difficulty in sitting still or had a 
headache during the ketamine administration; therefore, the 
EEG signals were not recorded during this period. The 
subjects were also allowed to sit in the rest area and read 
books to avoid fatigue or drowsiness. Subsequently, closed-
eye EEG signals were recorded during a second 10-min 
session to evaluate the effects of ketamine 240-min post-
infusion. Additionally, an experienced EEG specialist 
monitored the experimental conditions during the EEG 
recordings (e.g., ensuring that the location of the wearable 
EEG device did not shift). 
In addition, the quantitative depressive symptom ratings 
were recorded 0 min (baseline), 40 min (end of infusion), 80 
min, 120 min, 240 min, 24 hours (on day 2), 3 days, 4 days, 
5 days, 6 days, 7 days (one week) and 14 days (two weeks) 
post-treatment using the HDRS-17 (Fig. 1B). A “responder” 
was defined as an individual exhibiting at least a 45% 
reduction in the HDRS-17 score from baseline to 240-min 
post-treatment, and all other individuals were classified as 
non-responders.  
 
C. EEG Data Processing 
The EEG data were analyzed with EEGLAB, which is an 
open-source MATLAB toolbox for electrophysiological 
signal processing and analysis [33]. The analytical 
procedures used to process the EEG signals included 
bandpass filtering, time-frequency analysis, power 
estimation, asymmetry calculation, cordance assessment and 
antidepressant treatment response (ATR) measurement.  
Experienced EEG specialists were required to inspect the 
collected data to ensure that the raw EEG data did not have 
interference from artifacts despite the fact that the wearable 
EEG device has a built-in function to remove artifacts via 
real-time EEG signal enhancement. Then, the EEG data were 
bandpass-filtered from 1 to 12 Hz using a zero-phase finite 
impulse response filter. The processed EEG signals were 
subjected to further analysis. The main aim of the data 
processing approaches is to extract correct information from 
the brain, and then, the extracted features can classify  
 
 
 
Figure 1. EEG analytical procedures used in the ketamine 
experiment. (A) Wearable EEG device; (B) Ketamine infusion and 
EEG and HDRS recordings. 
different ketamine responses. 
 
 
a. EEG Power 
The processed time-series EEG data were transformed 
into the frequency domain with a 256-point fast Fourier 
transform using Welch’s method. Specifically, 10-min spans 
of data were analyzed with a 256-point moving window and 
a 128-point overlap. To increase the number of frequency 
bins, zero-padding was used to extend the length of the 
window, which can decrease the frequency interval and 
allows the power spectrum to appear smooth. Then, the 
windowed data were extended to 512 points by zero padding 
to calculate the power spectra, yielding an estimation of the 
power spectra from 1 to 12 Hz (frequency resolution: 0.5 
Hz). The power spectra (𝑃) of these windows were averaged 
and converted to a logarithmic scale. The relative EEG 
power was defined as the percentage of absolute power in 
any frequency band compared with the total power of the 
entire EEG spectrum. 
The absolute power was marked as 𝑃",$, and the relative 
power was expressed as 																															𝑃",$& =	𝑃",$/𝑃",$′                                        (1) 
where 𝑐  is the channel, and 𝑓  and 𝑓′  are the specific 
frequency band and all bands, respectively.  
Notably, the absolute and relative EEG powers of the four 
prefrontal channels were calculated from the delta (1–3.5 
Hz), theta (4–7.5 Hz), lower alpha (8–10 Hz) and upper alpha 
(10.5–12 Hz) bands. 
 
b. EEG Alpha Asymmetry 
We used the mid-prefrontal (Fp1/Fp2) and mid-lateral 
(AF7/AF8) hemispheric asymmetry index to establish a 
relative measure of the difference in EEG (lower and upper) 
alpha power between the right and left forehead areas. The 
formula used to calculate the left-right asymmetry score was 
defined as 																				𝐴,- = |(𝑃, − 𝑃-)	/	(𝑃, + 𝑃-)|                    (2)                       
 where 𝑃,  is the (lower/upper) alpha power that is left- 
lateralized at the baseline or post-treatment observations, and 𝑃-	is the corresponding right-lateralized power. 
 
c. EEG Theta Cordance 
 Theta cordance combines information from both the 
absolute and relative powers in the EEG theta band, which is 
less influenced by age, gender and severity associated with 
baseline depression. 
The absolute and relative EEG powers from Equation (1) 
were normalized and are expressed as follows: 																									𝑃34(",$) = 𝑃",$/𝑚𝑎𝑥(𝑃")                           (3) 																									𝑃3-(",$) = 𝑃8",$/𝑚𝑎𝑥(𝑃8")                           (4) 
where 𝑚𝑎𝑥(𝑃")  and 𝑚𝑎𝑥(𝑃8")  represent the maximum 
absolute power and maximum relative power, respectively. 
Then, theta cordance was calculated as follows: 
 𝐶𝑜𝑟𝑑𝑎𝑛𝑐𝑒",$ = (	𝑃34(",$) − 0.5) + (𝑃3-(",$) 	− 0.5)       (5) 
 
D. EEG Predictors 
The significant features from the EEG power analyses 
were treated as characteristic inputs to build a classification 
(prediction) model to distinguish ketamine effects at baseline. 
We considered a three-fold cross validation (66.7% training 
set and 33.3% testing set) to evaluate the classification 
Table I. Demographics, Clinical Profiles and Treatment Responses of the Ketamine and NS Groups 
Characteristics 
          Antidepressant Groups 
                                       Ketamine (n = 37)  
C: NS 
(n = 18) 
Bonferroni-adjusted 
       one-way 
      ANOVA p 
A: 0.5 mg/kg 
(n = 18) 
B: 0.2 mg/kg 
(n = 19) 
Demographics     
Sex, F:M 
Age, yrs 
16:2 
46.5 ± 11.6 
16:3 
48.1 ± 12.7 
13:5 
50.0 ± 7.6 
0.232 
0.340 
Clinical profiles 
Disease duration, yrs 
 
12.3 ± 8.3 
 
12.6 ± 9.3 
 
11.5 ± 7.3 
 
0.686 
Psychiatric comorbiditiesa 2.0 ± 1.6 2.1 ± 1.4 2.4 ± 1.5 0.658 
Current antidepressantsb 1.7 ± 0.7 1.8 ± 0.8 1.5 ± 0.7 0.718 
HDRS-17 Scores                     Groups A and B (n = 37) Group C (x) 
(n = 18)  Time points Responders (x) Non-responders 
0 min (baseline)  22.4 ± 4.3 (x = 0)          [p1= 0.485; p2 = 0.556] 24.8 ± 4.2 23.7 ± 4.5 (x = 0) 0.547 
40 min after treatment  13.6 ± 4.2 (x = 9)          [p1= 0.363; p2 = 0.335] 20.2 ± 4.6 20.9 ± 4.8 (x = 0) 0.359 
120 min after treatment  11.7 ± 4.5 (x = 11)        [p1= 0.043; p2 = 0.048]* 21.3 ± 4.9 20.1 ± 5.4 (x = 0) 0.047 
240 min after treatment  10.6 ± 3.7 (x = 16)        [p1= 0.037; p2 = 0.041]* 20.8 ± 5.3 19.2 ± 6.1 (x = 2) 0.040 
Day 2 (24 hours) after treatment  10.1 ± 3.9 (x = 9)          [p1= 0.043; p2 = 0.046]* 19.2 ± 5.7 18.9 ± 5.9 (x = 1) 0.046 
Day 3 after treatment  10.3 ± 4.4 (x = 9)          [p1= 0.051; p2 = 0.052] 19.4 ± 6.3 19.1 ± 6.1 (x = 1) 0.052 
Day 5 after treatment  10.7 ± 4.6 (x = 5)          [p1= 0.204; p2 = 0.198]  19.2 ± 6.2 19.2 ± 5.9 (x = 0) 0.203 
Day 7 after treatment  12.5 ± 5.0 (x = 3)          [p1= 0.438; p2 = 0.429]  19.7 ± 6.1 19.7 ± 5.8 (x = 0) 0.430 
x: Number of subjects who showed a response to ketamine.  
a Psychiatric comorbidities: chronic dysthymia, generalized anxiety disorder, panic disorder, social phobia and post-traumatic stress disorder. 
b Number of antidepressants used, including regular antidepressants, mood stabilizers and atypical antipsychotics. 
* p < 0.05 using Bonferroni-adjusted Tukey’s post hoc test (responders vs. non-responders or the NS group). p1 indicates the Bonferroni-adjusted p-values describing the HDRS-17 score differences between 
the responders and non-responders, and p2 indicates the Bonferroni-adjusted p-values describing the HDRS-17 score differences between the responders and the NS group. 
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performance of the mixed ketamine groups. Then, 
considering the prediction performances of ketamine groups 
A and B separately, we used the leave-one-subject-out cross-
validation method to evaluate the classification 
performances of group A or B. The classification model was 
built based on EEG features from the training set and then 
examined via the testing set. To predict ketamine effects, we 
classified the responders and non-responders using EEG 
features at baseline. In this study, we employed various 
machine learning classifiers to identify the EEG features that 
could be used for comparison; these classifiers included 
linear discriminant analysis (LDA), nearest mean classifier 
(NMSC), k-nearest neighbors (k-NN with k = 3), Parzen 
density estimation (PARZEN), perceptron classifier 
(PERLC), discriminative restricted Boltzmann machine 
(DRBMC) and support vector machine with radial basis  
function (SVMRBF) (PRTools, http://prtools.org/; LIBSVM 
toolbox, http://www.csie.ntu.edu.tw/~cjlin/libsvm/). In 
addition, we employed the assessment criteria of medical 
screening (sensitivity and specificity) and pattern recognition 
(recall, precision and F-measure) to evaluate the 
performance of the proposed predictors. 
 
E. Statistical Analysis 
 We analyzed the differences in demographics, clinical 
profiles and treatment responses among the groups (A: 0.5 
mg/kg ketamine, B: 0.2 mg/kg ketamine and C: NS) using 
one-way ANOVA tests, followed by correction of multiple 
comparisons by a sharpened Bonferroni procedure [34]. To 
investigate the differences in the EEG power between the 
responders and non-responders at baseline, we compared the 
EEG power values of the groups using the Wilcoxon rank-
sum test to determine whether the two independent samples 
(sample size < 30) of responders and non-responders had the 
same distribution. To determine the EEG changes between 
the baseline and post-infusion time points, we compared the 
pre- and post-infusion EEG power and asymmetry values 
using the Wilcoxon signed-rank test. The significance level 
was set to p < 0.05. Additionally, since there are many 
potential EEG parameters to examine regarding ketamine 
responses, the experiment-wise error may be significantly 
inflated. Given the number of comparisons analyzed, 
Hochberg’s sharpened Bonferroni [34] adjusted significant 
values (primary significance level p < 0.05 and secondary 
significance level p < 0.025) were used to reduce Type I 
error. Notably, the significantly different EEG baseline 
power (p < 0.05) between the responders and non-responders 
was treated as a characteristic input to build the classification 
(prediction) model. The statistical analyses were performed 
using the SPSS software package (version 15.0) and 
MATLAB (2011a) Bioinformatics Toolbox. 
 
III. RESULTS 
A.  Demographic, Clinical and Treatment-Response 
Characteristics  
 Fifty-five outpatients with TRD were enrolled in this 
study between October 2014 and April 2016, including 18, 
19 and 18 patients who received infusions of 0.5 mg/kg 
ketamine (group A), 0.2 mg/kg ketamine (group B) and 
normal saline (NS; group C), respectively. As shown in 
Table I, the demographic and clinical characteristics, 
including age, gender and clinical profiles (disease duration, 
psychiatric comorbidities and number of current 
antidepressants), were similar among the three groups. The 
concomitant medication regimens consisted of one 
antidepressant (36.4%), more than 2 antidepressants (21.8%) 
and a combination of antidepressants, mood stabilizers and 
atypical antipsychotics (41.8%). According to the MINI 
diagnosis, the most common psychiatric comorbidities were 
chronic dysthymia (52.7%), generalized anxiety disorder 
(GAD, 49.1%), panic disorder (32.7%), social phobia 
(10.9%) and post-traumatic stress disorder (10.9%). 
Approximately 54.5% of the patients had 2 or more 
comorbid psychiatric disorders. No significant differences in 
the prevalence of concomitant medications or comorbid 
psychiatric diseases were observed among the three groups.  
As shown in Fig. 2, we periodically recorded the changes 
in the HDRS-17 item scores of depression severity from 
baseline (pre-treatment) to 14 days post-treatment 
throughout the study. Notably, the ketamine responders 
showed a substantially greater improvement. Specifically, 
we did not observe a significant difference among groups A, 
B and C at baseline, but the responders had significantly 
lower HDRS scores than the non-responders or NS subjects 
120 min, 240 min, 24 hours (on day 2) and 3 days post-
treatment. According to the HDRS-17 estimates shown in 
Table I, a maximum of 16 responders was observed in the 
two ketamine groups (A: 0.5 mg/kg, n = 11; B: 0.2 mg/kg, n 
= 5) 240-min post-treatment. Specifically, 11 of the 18 (61%) 
patients infused with 0.5 mg/kg ketamine showed a 
significant response 240-min post-treatment, while only 5 of 
the 19 (26%) patients infused with 0.2 mg/kg ketamine 
showed a significant response at this time point.  
Nevertheless, only a few subjects in the NS group (n = 2) 
displayed an effective response during the same period. The 
HDRS-17 estimates also revealed that the most effective 
treatment outcome among all time points occurred at 240-
min post-ketamine infusion. Furthermore, the comparison of 
the HDRS-17 scores at baseline with those at 240-min post- 
treatment indicated that the severity of depression (mean ± 
standard deviation (SD)) in the ketamine responders 
decreased from 22.4 ± 4.3 to 10.6 ± 2.7 with a response rate 
of 52.7 ± 7.3%; the severity in the ketamine non-responders 
 
 
Figure 2. Changes in HDRS-17 scores from baseline to 14 days after  
infusion. 
decreased from 24.8 ± 4.2 to 20.8 ± 5.3 with a response rate 
of 18.4 ± 11.6%; and the severity in the NS group decreased  
 from 23.7 ± 4.5 to 19.2 ± 6.1 with a response rate of 20.1 ± 
13.0%. Notably, the severity of depression in the responders 
showed a significantly greater improvement than that in the 
non-responders or NS subjects (p < 0.05). 
 
B. Baseline Comparisons of EEG Power 
As shown in Fig. 3, we investigated baseline comparisons 
(pre-treatment) between the responders and non-responders 
by combing the continuous power spectra of all channels 
(AF7, Fp1, Fp2 and AF8). Compared with the non-
responders, the responders in the 0.5 mg/kg ketamine group 
showed lower relative EEG theta and lower alpha power (p 
< 0.05). There were no significant findings in the 0.2 mg/kg 
ketamine group.  
As indicated by the baseline comparisons of the mean 
power spectra shown in Table II, compared with the non-
responders in group A (0.5 mg/kg ketamine), the responders 
in group A had significantly (p < 0.05) weaker relative EEG 
power in the theta band on the AF7 and Fp2 channels and a 
decreasing trend towards relatively low alpha EEG power on 
the AF7 and Fp2 channels. In the baseline comparisons in 
group B (0.2 mg/kg ketamine), the responders showed  
significantly (p < 0.05) weaker relative EEG power in the 
theta band on the Fp2 channel than the non-responders. No 
differences were observed in the relative EEG power in the 
delta and high alpha bands between the responders and non-
responders in groups A or B. Additionally, the responders in 
group A showed significantly (p < 0.05) higher relative EEG 
power in the theta band on the Fp1 and Fp2 channels than the  
Table II. Relative EEG Power: Baseline Comparisons between the Ketamine Groups 
Relative 
Power 
Ketamine Groups (n = 37)   
A: 0.5 mg/kg dose (n = 18) B: 0.2 mg/kg dose (n = 19)  
 
pb Responders 
(n = 11) 
Non-
responders 
(n = 7) 
p  Responders (n = 5) 
Non-responders 
(n = 14) p  
AF7         
Delta 1.40 ± 0.26 1.34 ± 0.14 N  1.42 ± 0.18 1.33 ± 0.17 N  N 
Theta 0.89 ± 0.06 0.95 ± 0.06  0.042  0.91 ± 0.05 0.92 ± 0.07 N  N 
Low Alpha 0.81 ± 0.11 0.91 ± 0.09 0.045a  0.83 ± 0.25 0.90 ± 0.26 N  N 
High Alpha 0.76 ± 0.13 0.78 ± 0.08 N  0.79 ± 0.20 0.75 ± 0.14 N  N 
Fp1         
Delta 1.41 ± 0.21 1.33 ± 0.12 N  1.41 ± 0.19 1.32 ± 0.16 N  N 
Theta 0.89 ± 0.06 0.95 ± 0.06 N  0.93 ± 0.06 0.94 ± 0.07 N  0.038 
Low Alpha 0.84 ± 0.10 0.90 ± 0.11 N  0.85 ± 0.20 0.99 ± 0.25 N  N 
High Alpha 0.74 ± 0.09 0.77 ± 0.08 N  0.80 ± 0.20 0.73 ± 0.15 N  N 
Fp2         
Delta 1.42 ± 0.20 1.28 ± 0.15 N  1.42 ± 0.20 1.28 ± 0.16 N  N 
Theta 0.88 ± 0.03 0.96 ± 0.06  0.035  0.91 ± 0.04 0.95 ± 0.05 0.028  0.042 
Low Alpha 0.81 ± 0.11 0.92 ± 0.07 0.039a  0.83 ± 0.18 0.91 ± 0.27 N  N 
High Alpha 0.74 ± 0.12 0.81 ± 0.09 N  0.79 ± 0.18 0.78 ± 0.17 N  N 
AF8         
Delta 1.41 ± 0.26 1.32 ± 0.17 N  1.40 ± 0.21 1.30 ± 0.18 N  N 
Theta 0.89 ± 0.06 0.95 ± 0.07 N  0.92 ± 0.07 0.93 ± 0.05 N  N 
Low Alpha 0.82 ± 0.13 0.91 ± 0.06 N  0.84 ± 0.21 0.90 ± 0.26 N  N 
High Alpha 0.75 ± 0.15 0.78 ± 0.12 N  0.80 ± 0.15 0.76 ± 0.16 N  N 
          
 
Delta: (1-3.5 Hz) / (1-12 Hz) EEG power (dB). 
Theta: (4-7.5 Hz) / (1-12 Hz) EEG power (dB).  
Low Alpha: (8-10 Hz) / (1-12 Hz) EEG power (dB). 
High Alpha: (10.5-12 Hz) / (1-12 Hz) EEG power (dB). 
p-value: measured using the Wilcoxon rank-sum test with a significant p-value < 0.05.  
             1) N: Not significant (p ≥ .05).  
             2) Significance values were adjusted using a sharpened Bonferroni correction for multiple comparisons (primary significance level p    
                 < 0.05 and secondary significance level p < 0.025). 
a Not statistically significant after sharpened Bonferroni adjustment. 
b Comparisons of the responders in groups A and B. 
 
 
 
Figure 3. Baseline comparisons of the EEG power in the 
ketamine groups (left: 0.5 mg/kg, right: 0.2 mg/kg). Notably, the red 
and blue traces represent the mean ± SD of the EEG power in the 
responders and non-responders, respectively. 
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responders in group B, indicating that for some patients, only 
a low ketamine dose (0.2 mg/kg) is needed to elicit a 
significant effect on EEG power.  
 
C. Comparisons of Baseline and 240 min Post-treatment 
 As shown in Table Ш, groups A and B were combined, 
and the responders and non-responders in this group were 
considered the active ketamine group and inactive ketamine 
Table III. Relative EEG Power, Alpha Asymmetry and Theta Cordance: Baseline vs. 240-min Post-treatment 
 
0.5 or 0.2 mg/kg ketamine dose     
NS 
(n = 18) 
 
Active group: Responders 
 (n = 16)  
 
Inactive group: Non-responders 
 (n = 21) 
 
 
Index 0 minb 240 minc p  0 minb 240 minc p   0 min
b 240 minc p 
 
Relative Power 
 
AF7 
           
Delta 1.40 ± 0.26 1.36 ± 0.26 N  1.31 ± 0.16 1.29 ± 0.21 N  1.16 ± 0.61 1.10 ± 0.57 N 
Theta 0.90 ± 0.07 0.88 ± 0.08 N  0.95 ± 0.06 0.95 ± 0.13 N  0.91 ± 0.11 0.91 ± 0.11 N 
Low Alpha 0.85 ± 0.15 0.96 ± 0.23 0.010  0.99 ± 0.25 0.97 ± 0.18 N  1.01 ± 0.27 1.08 ± 0.21 N 
High Alpha 0.80 ± 0.19 0.85 ± 0.21 N  0.74 ± 0.12 0.78 ± 0.17 N  0.97 ± 0.58 1.01 ± 0.52 N 
 
Fp1 
      
Delta 1.38 ± 0.21 1.31 ± 0.25 N  1.32 ± 0.12 1.29 ± 0.17 N  1.21 ± 0.56 1.18 ± 0.44 N 
Theta 0.93 ± 0.08 0.91 ± 0.08 N  0.96 ± 0.06 0.97 ± 0.12 N  0.95 ± 0.11 0.93 ± 0.10 N 
Low Alpha 0.87 ± 0.14 0.96 ± 0.18 0.023  0.98 ± 0.20 0.97 ± 0.18 N  0.95 ± 0.25 1.00 ± 0.17 N 
High Alpha 0.78 ± 0.13 0.84 ± 0.19 N  0.73 ± 0.13 0.75 ± 0.16 N  0.88 ± 0.48 0.92 ± 0.43 N 
 
Fp2 
      
Delta 1.41 ± 0.20 1.30 ± 0.22 N  1.26 ± 0.15 1.25 ± 0.19 N  1.10 ± 0.64 1.11 ± 0.50 N 
Theta 0.90 ± 0.08 0.90 ± 0.09 N  0.97 ± 0.07 0.97 ± 0.12 N  0.96 ± 0.08 0.93 ± 0.22 N 
Low Alpha 0.85 ± 0.15 0.98 ± 0.21 0.020  1.00 ± 0.22 1.00 ± 0.20 N  1.01 ± 0.29 1.06 ± 0.19 N 
High Alpha 0.80 ± 0.13 0.87 ± 0.23 0.023  0.75 ± 0.16 0.79 ± 0.15 N  0.95 ± 0.57 0.98 ± 0.52 N 
 
AF8 
     
Delta 1.39 ± 0.43 1.30 ± 0.20 N  1.30 ± 0.17 1.28 ± 0.19 N  1.59 ± 1.20 2.01 ± 5.63 N 
Theta 0.92 ± 0.12 0.90 ± 0.08 N  0.95 ± 0.08 0.96 ± 0.11 N  0.95 ± 0.14 0.89 ± 0.20 N 
Low Alpha 0.85 ± 0.16 0.98 ± 0.19 0.011  0.99 ± 0.22 0.97 ± 0.19 N  0.82 ± 0.68 0.50 ± 0.12 N 
High Alpha 0.80 ± 0.17 0.86 ± 0.15 0.045a  0.76 ± 0.12 0.79 ± 0.15 N  0.53 ± 1.14 0.36 ± 4.29 N 
            
Alpha Asymmetry 
 
AF8 -AF7 
           
Low Alpha 0.12 ± 0.14 0.08 ± 0.12 N  0.06 ± 0.10 0.07 ± 0.09 N  0.06 ± 0.07 0.03 ± 0.03 N 
High Alpha 0.11 ± 0.12 0.05 ± 0.04 N  0.10 ± 0.12 0.07 ± 0.08 N  0.07 ± 0.08 0.04 ± 0.04 N 
 
Fp2 -Fp1 
           
Low Alpha 0.11 ± 0.12 0.03 ± 0.02 0.042  0.09 ± 0.11 0.06 ± 0.07 N  0.43 ± 1.48 0.09 ± 0.11 N 
High Alpha 0.13 ± 0.18 0.07 ± 0.07 N  0.08 ± 0.10 0.10 ± 0.11 N  0.19 ± 0.43 0.10 ± 0.12 N 
            
Theta Cordance  
AF7 1.55 ± 0.07 1.42 ± 0.08  0.041a  1.48 ± 0.08 1.39 ± 0.09 N  1.48 ± 0.08 1.41 ± 0.08 N 
Fp1 1.54 ± 0.05 1.41 ± 0.06 0.014  1.50 ± 0.06 1.41 ± 0.07 N  1.51 ± 0.07 1.41 ± 0.09 N 
Fp2 1.53 ± 0.05 1.42 ± 0.06 0.023  1.49 ± 0.07 1.40 ± 0.07 N  1.50 ± 0.06 1.40 ± 0.08 N 
AF8 1.55 ± 0.08 1.41 ± 0.08  0.046a  1.47 ± 0.09 1.39 ± 0.08 N  1.48 ± 0.09 1.39 ± 0.09 N 
            
 
Delta: (1-3.5 Hz) / (1-12 Hz) EEG power (dB). 
Theta: (4-7.5 Hz) / (1-12 Hz) EEG power (dB).  
Low Alpha: (8-10 Hz) / (1-12 Hz) EEG power (dB). 
High Alpha: (10.5-12 Hz) / (1-12 Hz) EEG power (dB). 
p-value: measured using Wilcoxon rank-sum test with a significant p-value < 0.05.  
             1) N: Not significant (p ≥ 0.05).  
             2) Significance values were adjusted using sharpened Bonferroni correction for multiple  
                 comparisons (primary significance level p < 0.05 and secondary significance  
                 level p < 0.025). 
a Not statistically significant after sharpened Bonferroni adjustment. 
b Baseline (pre-treatment) period.  
c 240-min post-treatment period. 
 
 
group, respectively. We compared the relative EEG power 
before and after the ketamine or NS infusion (0 min vs. 240  
min). The EEG power in the active ketamine group 
showed a significant (p < 0.05) increase in the low alpha 
band on the AF7, Fp1, Fp2 and AF8 channels 240-min post-
treatment compared with that at baseline (pre-treatment), but 
no changes were observed in the delta or theta band. The 
relative  
EEG power in the inactive ketamine and placebo groups 
generally did not differ from the baseline values. 
Table III also shows the differences in hemispheric 
asymmetry in the low and high alpha bands from the baseline 
to 240 min post-treatment observations. The midline (Fp1-
Fp2) low alpha asymmetry in the active ketamine group 
showed a significant decrease (p = 0.042, from 0.11 ± 0.12 
to 0.03 ± 0.02) after the ketamine treatment (p < 0.05), 
whereas the hemispheric alpha asymmetry in the inactive 
ketamine group and the NS group was similar between the 
baseline and post-treatment observations.  
Additionally, we compared the EEG theta cordance from 
baseline to 240-min post-treatment (Table III). The 
responders showed significantly decreased EEG theta 
cordance in all channels (p < 0.05). Specifically, after the 
ketamine treatment, the responders showed a significantly 
decreased EEG theta cordance on the AF7 (p = 0.041, from 
1.55 ± 0.07 to 1.42 ± 0.08), Fp1 (p = 0.014, from 1.54 ± 0.05 
to 1.41 ± 0.06), Fp2 (p = 0.023, from 1.53 ± 0.05 to 1.42 ± 
0.06) and AF8 (p = 0.046, from 1.55 ± 0.08 to 1.41 ± 0.08) 
channels, while the EEG theta cordance in the inactive 
ketamine group or the NS group showed no significant 
differences. Briefly, early changes in the EEG power, 
asymmetry and cordance were observed in the  
patients who actively responded to the ketamine infusion but 
not in those who received NS. 
In summary, Table III presents the comparisons of 
baseline and 240 min post-treatment within one group (intra-
subject EEG variabilities), which can identify ketamine 
responses and potentially contribute to a regression analysis 
in the future to estimate the relationships among EEG 
variables if long-term EEG recordings of TRD patients are 
conducted. 
 
D. Performances of EEG Predictors 
The classification performances (mean accuracy ± SD) 
are summarized in Table IV. Specifically, we used seven 
machine learning classifiers (LDA, NMSC, 3-NN, PARZEN, 
PERLC, DRBMC and SVMRBF) to separately train a 
prediction model using two-thirds of the enrolled subjects (n 
= 25, including 11 responders and 14 non-responders) and 
then test the performance of the classifiers using the 
remaining subjects (n = 12). The significant EEG features 
from Table II (e.g., EEG power in relative theta or low alpha 
frequency band) were selected as input features.  
In this study, we also considered the imbalanced problem; 
therefore, we randomly over-sampled 3 samples from the 
training dataset of the responder group to increase the sample 
of minority. Thus, the training dataset was balanced between 
the responder (n = 14) and non-responder (n = 14) groups. 
The EEG features combining the relative theta with the low 
alpha power had the best performance and the highest 
accuracy (81.3 ± 9.5%). The predictor with the best 
performance exhibited 82.1 ± 8.6% sensitivity, 91.9 ± 7.4% 
specificity, 81.9 ± 8.6% recall, 92.0 ± 8.2% precision and 
57.2 ± 4.4% F-measure based on our SVMRBF (parameters: 𝑐 = 10, 𝛾 = 1) predictor.  
Then, we considered the classification performances of 
ketamine groups A and B separately. Regarding group A, we 
randomly over-sampled 2 samples from the training dataset 
of the non-responder group to increase the sample of 
minority. Thus, the training dataset was balanced between 
the responder (n = 7) and non-responder (n = 7) groups. The 
SVMRBF-based predictor (parameters: c = 10, 𝛾  = 1) 
achieved the highest accuracy (80.6 ± 8.3%), sensitivity 
(81.7 ± 8.5%), specificity (88.3 ± 7.5%), recall (80.6 ± 7.8%), 
precision (91.1 ± 7.7%) and F-measure (57.3 ± 4.5%). 
Regarding group B, we randomly over-sampled 6 samples 
from the training dataset of the responder group to increase 
the sample of minority. Thus, the training dataset was 
balanced between the responder (n = 9) and non-responder 
(n = 9) groups. The SVMRBF-based predictor (parameters: 
c = 10, 𝛾 = 1) achieved the highest accuracy (78.4 ± 9.6%), 
sensitivity (79.3 ± 8.8%), specificity (84.2 ± 7.7%), recall 
(78.5 ± 8.0%), precision (87.0 ± 7.9%) and F-measure (52.6 
± 5.5%).  
When the other EEG baseline features (e.g., alpha 
asymmetry or theta cordance) were treated as characteristic 
inputs to build the classification (prediction) model, the 
 
Table IV. Performances of EEG Power Predictors 
 
 
Predictors 
 
 
Accuracy ± SD by EEG Frequency (%)  
Mixed Ketamine Groups 0.5 mg/kg Ketamine Group 0.2 mg/kg Ketamine Group 
Theta Low alpha Theta + Low alpha Theta Low alpha 
Theta + 
Low alpha Theta Low alpha 
Theta + 
Low alpha 
LDA 69.8 ± 6.5 60.2 ± 5.1 71.6 ± 7.4 70.2 ± 6.0 64.5 ± 6.0 72.1 ± 7.6 69.8 ± 6.5 60.2 ± 5.1 69.6 ± 8.7 
NMSC 61.4 ± 5.4 62.5 ± 6.9 76.2 ± 9.3 65.3 ± 5.8 64.6 ± 6.3 78.3 ± 8.9 61.4 ± 5.4 62.5 ± 6.9 77.1 ± 9.0 
3-NN 67.5 ± 6.5 61.1 ± 5.3 74.2 ± 9.7 68.7 ± 6.2 63.2 ± 5.8 75.2 ± 9.3 67.5 ± 6.5 61.1 ± 5.3 73.5 ± 9.1 
PARZEN 67.8 ± 6.6 62.0 ± 5.8 75.9 ± 7.8 70.9 ± 6.1 63.5 ± 5.7 75.3 ± 8.0 67.8 ± 6.6 62.0 ± 5.9 74.1 ± 8.0 
PERLC 60.6 ± 5.9 54.6 ± 5.4 70.4 ± 6.2 64.2 ± 6.5 59.4 ± 5.8 71.6 ± 5.9 60.6 ± 5.9 55.3 ± 6.0 69.7 ± 6.0 
DRBMC 61.5 ± 6.5 57.3 ± 7.4 71.1 ± 4.7 67.3 ± 6.4 55.8 ± 7.2 73.0 ± 5.1 61.5 ± 6.5 56.4 ± 7.5 70.3 ± 5.2 
SVMRBF 73.5 ± 9.5 63.1 ± 9.8 81.3 ± 9.5 77.6 ± 8.6 69.3 ± 7.4 80.6 ± 8.3 73.5 ± 9.5 64.3 ± 9.5 78.4 ± 9.6 
 
Abbreviations: LDA: linear discriminant analysis; NMSC: nearest mean classifier; 3-NN: k-nearest neighbors with k = 3; PARZEN: Parzen density estimation; PERLC: perceptron classifier;  
DRBMC: discriminative restricted Boltzmann machine; SVMRBF: support vector machine with radial basis function. 
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performances were inferior to the EEG power predictors. 
Specifically, the EEG alpha asymmetry predictors could only 
achieve 73.1 ± 9.2% accuracy, and the EEG theta cordance 
predictors could only achieve 69.5 ± 8.6% accuracy. In 
summary, our proposed model could predict the 
antidepressant effects after the administration of ketamine 
(240 min) to distinguish the responders and non-responders 
at the baseline EEG power.  
 
IV. DISCUSSION 
Our study investigated baseline and post-ketamine 
infusion forehead EEG patterns in patients with TRD under 
randomized, double-blind, placebo-controlled conditions. 
The rapid antidepressant effects of low-dose ketamine are 
reflected by changes in the EEG power spectra and 
asymmetry in the prefrontal region. We differentiated 
responders from non-responders who received 0.5 or 0.2 
mg/kg ketamine infusions based on their baseline EEG and 
explored the EEG changes during the early (240 min) post-
infusion period in the ketamine responders, ketamine non-
responders and NS controls. According to Table III, the 
ketamine responders displayed weaker relative EEG power 
in the theta bands at baseline, increased relative EEG power 
and decreased asymmetry in the low alpha band; these 
responses were correlated with the rapid antidepressant 
effects of ketamine. Notably, our study used machine 
learning technology (Table IV) and wearable EEG devices to 
distinguish the ketamine responders from non-responders 
with 81.3 ± 9.5% accuracy, 82.1 ± 8.6% sensitivity and 91.9 
± 7.4% specificity; this method may have the potential to 
predict rapid antidepressant effects. Our forehead EEG 
patterns suggested that the baseline and early changes in 
prefrontal activities may predict individual antidepressant 
responses to a mixed dose of ketamine. 
The dose-related efficacy of ketamine in the current study 
is consistent with an earlier meta-analysis that suggested that 
higher ketamine doses were more effective across several 
studies [35]. Moreover, one study investigating the S-isomer 
of ketamine suggested that both the 0.2 and 0.4 mg/kg doses 
were effective [36]. Nevertheless, R/S-ketamine has 
routinely been infused in previous studies at a dose of 0.5 
mg/kg to treat depression [27, 37] but has never been tested 
at a lower dose (e.g., 0.2 mg/kg). Therefore, testing a lower 
R/S-ketamine dose to determine whether the antidepressant 
efficacy could be maintained while minimizing adverse 
psychoactive effects, such as dissociation, could be of 
interest. Furthermore, according to Table I, our findings 
show that 2 patients in group C responded to NS, which is 
the placebo effect in clinical trials. Prior studies have shown 
that depressed patients who are treated with placebo may 
exhibit substantial reductions in symptoms [38]. The placebo 
effect involves psychological factors, including frequent 
visits, the infusion procedure, care from medical staff 
members, and some brain mechanisms of the placebo effect. 
Additionally, of particular interest, the efficacy of ketamine 
in Han Chinese, e.g., Taiwanese, patients [39] has been noted, 
but the generalizability of ketamine efficacy to populations 
of diverse races and ethnicities has not been established. 
Therefore, our study addresses this need by examining the 
effect of ketamine in a Taiwanese population. Our finding 
that Taiwanese patients may experience good antidepressant 
effects with a 61% response rate to the standard (0.5 mg/kg) 
ketamine dose is consistent with our recent adjunctive 
ketamine study [39]. 
 
A. Baseline EEG Patterns 
Baseline measures of prefrontal electrical activity have 
been highlighted as EEG biosignatures of antidepressant 
responses. Theta and low alpha activity have been linked to 
processing functions related to emotion [40], and pre-
treatment theta activity has been associated with the 
antidepressant response localized to the anterior cingulate 
cortex (ACC) [41]. According to our baseline results, as 
shown in Table II, the patients with TRD who exhibited an 
effective ketamine response exhibited lower relative EEG 
power in the theta and low alpha bands, whereas the absolute 
EEG power differences were not significant in any of the 
frequency bands. Moreover, according to our results, as 
described in section III-A, the 0.5 mg/kg dose of ketamine 
produced better response effects than the 0.2 mg/kg dose 
(response rate = 61.1% vs. 26.3%) 4 hours after treatment, 
which may be explained by the fact that most patients 
responded to the 0.5 mg/kg dose, whereas the lower dose (0.2 
mg/kg) affected only some patients with weak EEG power in 
the theta band at baseline. Thus, patients who have relatively 
weak theta waves at baseline may require a normal low dose 
(0.5 mg/kg) of ketamine; otherwise, they could require a 
slightly lower dose (0.2 mg/kg). Our baseline EEG power 
results are consistent with a previous study using selective 
serotonin reuptake inhibitor (SSRI) treatment [17] but 
partially contradict a study that associated fluoxetine and 
venlafaxine antidepressant responses with overall higher 
baseline EEG theta power [16]. The differences in these 
findings may be related to the differences in the mechanisms 
of action of rapid antidepressants (e.g., ketamine) and 
conventional antidepressants. Regarding the biological 
mechanism derived from theta and alpha activity, lower 
baseline theta and alpha activity may be positively correlated 
with glucose metabolism in ketamine responders [42] and 
reflect lower arousal associated with lower serotonergic 
activity [18]. Additionally, the current interest in using 
baseline biosignatures to predict the treatment response in 
patients with depression has been reported [43, 44]. 
Prefrontal EEG power at baseline was reported to predict the 
SSRI antidepressant response with 63% [17] and 88% 
accuracy [45] in two studies using machine learning 
technology, suggesting that the use of forehead EEG patterns 
has potential for building a baseline predictor of the 
responses to ketamine treatment.  
 
B. Early Changes in Prefrontal EEG After Ketamine 
Treatment 
EEG is generally used to evaluate antidepressant 
outcomes by examining pre- to post-treatment EEG changes 
[44]. Using baseline relative EEG measurements and early 
post-treatment changes, significantly lower alpha power has 
been observed in depressed patients compared with normal 
controls [46], and significantly higher alpha asymmetry has 
been observed in depressed patients compared with that in 
normal controls in previous baseline EEG studies [47]. These 
findings revealed EEG changes in the active ketamine group 
compared with the normal controls. Based on our findings, 
as shown in Table III, the early (240 min) changes in the 
post-treatment responders, which are characterized by 
increased relative power and decreased asymmetry in the low 
alpha band, were required for the ketamine-specific rapid 
antidepressant effect. Our results revealed increased 
prefrontal alpha activity after effective responses. This 
finding is consistent with a previous study showing that 
elevated resting rACC activity is correlated with the ATR 
through adaptive self-referential functions, such as 
mindfulness and non-evaluative self-focus [48]. The 
decreased EEG asymmetry may be positively correlated with 
lower behavioral activation sensitivity and inversely 
correlated with negative affect and behavioral inhibition [47, 
49]. Regarding EEG cordance, our findings showed a 
decrease in theta cordance at prefrontal leads compared to 
that at baseline; however, this finding was not observed in 
the non-responders or patients treated with placebo. This 
trend is similar to that reported in prior studies using other 
antidepressant treatments [24, 25]. 
However, although correlations between these EEG 
signatures and the response to antidepressant treatment have 
been proposed, none have been validated to date because 
recent findings have not been consistently replicated. 
Jaworska, et al. [50] reported an elevated absolute alpha 
power in depressed patients. This finding was replicated in a 
large sample with increased alpha and theta EEG power 
among patients during the early stages of depression [51]. 
Other studies failed to show decreased alpha activity in 
patients with TRD [46]. In addition, the EEG differences 
have been associated with improved antidepressant treatment 
outcomes. For example, an increased EEG alpha power has 
been shown to differentiate responders from non-responders 
following 3 to 6 weeks of treatment with SSRIs, such as 
paroxetine and fluoxetine [21]. Nevertheless, many studies 
have failed to replicate the alpha asymmetry findings in 
depression [20, 46]. In addition to alpha activity measures, 
one prognostic study reported that reduced theta power was 
related to the response to antidepressant treatments [17]. In 
contrast, increased theta activity has been observed in 
responders 6 weeks after treatment with SSRIs [52]. These 
studies are limited due to the mixed results of theta and alpha 
activity associated with different antidepressant responses. 
 
C. Ketamine Outcome Prediction 
Current research has focused on using baseline patterns 
to predict treatment responses in depression [43, 44]. 
Abnormalities in theta and alpha EEG activities have been 
associated with major depression [11, 12, 15, 16, 18], 
suggesting that the EEG parameters of the theta and alpha 
bands could serve as significant biosignatures and offer the 
potential to build a baseline predictor. A prior study reported 
that the baseline prefrontal relative theta power could predict 
the antidepressant response to SSRIs with 63% accuracy [17]. 
Another more recent study reported that baseline prediction 
improved to 87.9% accuracy for SSRI treatment using 
machine-learning technology and various patterns [45]. The 
baseline results of our study (Table IV) provided patterns of 
relative theta and low alpha EEG power that predict the 
effect of ketamine with 81.3 ± 9.5% accuracy, 82.1 ± 8.6% 
sensitivity and 91.9 ± 7.4% specificity based on the 
SVMRBF predictor. This baseline EEG predictor may offer 
a supporting reference to help doctors select an appropriate 
ketamine dose for depressed patients. 
In contrast to traditional antidepressants, ketamine 
treatment can rapidly reduce depressive symptoms within 4 
hours post-treatment. Considering the rapid effects of 
ketamine observed in our manuscript, we labeled the 
responders and non-responders 4 hours post-treatment. If we 
labeled the responders and non-responders at other time 
instances, e.g., after 4 hours post-treatment, the numbers of 
responders would decease instantly due to the reduced 
effects of ketamine; therefore, this methodology is not 
considered an optimized label and training model, 
accounting for the unbalanced samples after 4 hours post-
treatment (e.g., increasing the numbers of responders and 
decreasing the numbers of non-responders). 
 
D.   Wearable Forehead EEG with Dry Sensors 
Notably, the identified EEG signatures have the potential 
to distinguish ketamine responders and non-responders at 
baseline and predict the levels of antidepressant responses to 
ketamine with further clinical usage. Due to the development 
of sensor technology, an alternative to conventional EEG 
devices with wet electrodes and cables has emerged. 
Wearable and wireless EEG devices with dry-contact sensors 
(Fig. 1-A) have led to a reduction in the amount of 
preparatory work required for long-term monitoring and 
daily use [13, 14, 53] and have successfully been used to 
monitor brain activity in sleep and driving experiments [54, 
55]. Wearable wireless EEG devices with dry sensors offer a 
promising tool for the daily monitoring of depression. 
Forehead EEG patterns could potentially be used to estimate 
ketamine responses in daily life via a wearable EEG-based 
system. 
 
E. Limitations 
The major strength of this study was the sizeable number 
of patients tested using a randomized and placebo-controlled 
design. However, this study also had limitations. First, the 
responders were defined as subjects with at least a 45% 
reduction in baseline depression symptoms (HDRS-17) 
instead of the popular criterion of a 50% reduction as the 
sample size of the responders was too small to conduct 
statistical analyses. Furthermore, we combined the data from 
groups A and B in the analysis because of the small number 
of responders in group B. In the future, we could overcome 
this problem by increasing the total number of participants in 
each dose group to obtain a better comparison of the 
responders at each dose. Second, the recruitment in the study 
was limited to Asian patients with TRD, which may have 
yielded results that cannot be generalized to other 
************* 
 
populations. Wider application would require a broader 
range of participants of different races. Third, none of our 
participants reported a significant response with traditional 
antidepressant treatments; therefore, the EEG dynamics were 
primarily influenced by the effect of ketamine. Nevertheless, 
EEG changes may be affected by the concomitant use of 
other antidepressant treatments. Fourth, the results of the 
present study provide evidence supporting the involvement 
of EEG power and asymmetry in the low alpha band on the 
240-min antidepressant effects of a single-dose ketamine 
treatment in patients with TRD. However, further research is 
required to determine how the changes in EEG power and 
asymmetry are related to the antidepressant effects of 
ketamine at other time points (days 2, 3, 4, etc.). Finally, as 
our wearable headband-style EEG equipment is limited by 
the placement of the electrodes (prefrontal area), this device 
is not feasible for covering the entire brain. Thus, our 
findings represent only regional specificity for prefrontal 
EEG dynamics. We are unsure whether the effects of 
ketamine could also involve the EEG dynamics of other 
brain regions (e.g., parietal or occipital cortices). Due to this 
limitation of the electrode placements, we plan to use a 
multichannel EEG device to obtain a wider range of brain 
signals in the future. 
 
V. CONCLUSION 
Our randomized, double-blind, placebo-controlled study 
revealed the EEG patterns at baseline and in response to a 
mixed-dose ketamine treatment in patients with TRD. The 
results provided initial evidence that ketamine responders 
had weaker baseline EEG theta power, which functioned as 
an EEG-based predictor with 81.3 ± 9.5% accuracy, 82.1 ± 
8.6% sensitivity and 91.9 ± 7.4% specificity. Moreover, an 
active ketamine response was accompanied by increased 
alpha power and decreased alpha asymmetry. In addition, 
Taiwanese patients may exhibit a good antidepressant 
response to the standard (0.5 mg/kg) ketamine dose. These 
insights provide important information about potential 
targets for the baseline identification of ketamine responders 
and the underpinnings of the early effects of ketamine on 
TRD.  
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